At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 3, 2026 at 16:05 ET
ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is the initiation of Himalayas-1, a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, and a clinical collaboration with Bayer for darolutamide supply. Cash runway extends into 2H 2028, with key data catalysts expected in 2H 2026.
- Q2 2026 net loss $(0.38)/share vs consensus $(0.36), a -5.6% miss
- Initiated global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC
- Entered clinical trial collaboration with Bayer to receive darolutamide at no cost for Himalayas-1
- Cash and investments $387.6M, expected runway into 2H 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access